Today, JAMA published Toward a Healthier Future Through Obesity Prevention and Care: The #JAMASummit Report on Obesity.
🔗 Read the full report: ja.ma/3V5L2OD
#ObesityWeek #OW2026
Join JAMA and JAMA Network Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, and leading experts in #obesity research, treatment, and policy for an inside look at Toward a Healthier Future: The #JAMASummit Report on Obesity.
➡️ Register now: ja.ma/4t4day5
For patients with resectable locally advanced #HeadAndNeckSquamousCellCarcinoma, perioperative camrelizumab plus chemotherapy improved 2-year event-free survival vs standard surgery-based treatment. ja.ma/4kaMIR0
For patients with #NasopharyngealCarcinoma receiving chemoradiotherapy, early oral nutritional supplementation reduced significant weight loss and severe radiation-induced oral mucositis compared with routine supplementation
ja.ma/4kMGJ57
In ERBB2-positive metastatic #BreastCancer, first-line treatment is shifting beyond taxane-based induction toward newer regimens and expanded maintenance options that may change treatment sequencing and duration. ja.ma/3UHbgqv
Among trainees providing #CancerCare, representation of physicians from groups underrepresented in medicine increased after 2020, but still did not match the diversity of the general US population in 2025. ja.ma/4zoqO1l
In 2027, JAMA will convene leaders across #medicine, research, #technology, industry, and #policy to address how #AI will reshape health care and biomedical science.
Learn more: ja.ma/4kAk3oA
#HealthAfterAI #JAMASummit
📝 JAMA Oncology Patient Page: Supplements and Wellness Products During #Cancer Care This Patient Page discusses safety when taking supplements and wellness products during cancer treatment. ja.ma/3W97574
A 79-year-old woman with high-risk myelodysplastic syndrome treated with 5-azacitidine presented with painful ulcers on the tongue and right lower extremity. What is your diagnosis? ja.ma/4B6SpW4
📑 This JAMA Oncology review discusses #Chemotherapy decision-making support tools and updated evidence guiding therapeutic decision-making among older adults with early-stage #BreastCancer. ja.ma/3UlZi5o
1
4
1,459
📣 JAMA and the JAMA Network journals are issuing a call for papers on Women's Health.
➡️ Manuscripts submitted by November 15, 2026, will have the best chance for consideration for simultaneous publication on International Women’s Day.
🔗 Learn more: ja.ma/48a7OYp
In US #Cancer clinical trials, industry sponsors were more likely to focus on single-agent drug therapies, while federal sponsors were more likely to evaluate prevention and supportive care interventions. ja.ma/4B5fVmv
5
922
Presented at #ESMO26 from @JAMA_current:
In low erythroblastic oncogene B 2 (ERBB2) advanced #BreastCancer, trastuzumab rezetecan showed benefit in hormone receptor–positive and hormone receptor-negative disease.
ja.ma/3W0Jp4W
Presented at #ESMO26 from @JAMA_current: For low erythroblastic oncogene B 2 (ERBB2) advanced #BreastCancer, trastuzumab rezetecan improved progression-free survival vs chemotherapy in both chemotherapy-naive patients and the overall population.
ja.ma/4dRU6Nf
In Denmark, #Meningioma incidence increased from 2010 to 2023, but #Surgery and #Radiotherapy rates remained stable, indicating that more diagnoses did not lead to more treatment. ja.ma/47UVE5A
Among patients with early #TripleNegativeBreastCancer, tissue-free #ctDNA detection during molecular residual disease surveillance was strongly prognostic for recurrence and supported testing when tumor tissue was unavailable. ja.ma/4zvbb83
In patients with #ProstateCancer receiving #AdaptiveTherapy, mathematical biomarkers from first-cycle prostate-specific antigen (#PSA) dynamics predicted time to progression and overall survival better than standard PSA metrics. ja.ma/47Py4XY
#ColorectalCancer mortality declined nationally among US adults aged ≥45 years from 2000 to 2019, but county-level disparities persisted, with some counties exceeding 100 deaths per 100 000 among American Indian or Alaska Native and Black populations. ja.ma/47lx9hP
In #CancerCare, biosimilar entry for bevacizumab, rituximab, and trastuzumab was associated with lower reference product prices and market share, along with lower payer and patient costs. ja.ma/4zwEtTG
Among men with #ProstateCancer starting concurrent androgen deprivation therapy and an androgen receptor pathway inhibitor, #MetabolicSyndrome and related abnormalities were frequently documented early, with hypertension the most common outcome. ja.ma/4ilWGgU




